These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21844507)

  • 1. Cardiovascular toxicity of androgen deprivation therapy: a new door opens.
    Alibhai SM
    J Clin Oncol; 2011 Sep; 29(26):3500-2. PubMed ID: 21844507
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone.
    Aragon-Ching JB
    J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519
    [No Abstract]   [Full Text] [Related]  

  • 3. Researchers probe consequences of androgen deprivation for prostate cancer.
    Friedrich MJ
    JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
    [No Abstract]   [Full Text] [Related]  

  • 4. Competing risks for patients with localized prostate cancer.
    Seidenfeld J; Samson DJ; Albertsen PC
    J Natl Cancer Inst; 2007 Oct; 99(20):1498-9. PubMed ID: 17925533
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
    Hu JR; Duncan MS; Morgans AK; Brown JD; Meijers WC; Freiberg MS; Salem JE; Beckman JA; Moslehi JJ
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e55-e64. PubMed ID: 31969015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risks of androgen deprivation therapy.
    Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
    Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
    Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
    J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: androgen deprivation therapy: impact on quality of life and cardiovascular health.
    Shah SI; Cafferty FH; Langley RE; Abel PD
    J Sex Med; 2014 Jan; 11(1):314-5. PubMed ID: 24112553
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular risk profile of veteran men beginning androgen deprivation therapy.
    Williams L; Hicks E; Kwan L; Litwin M; Maliski S
    J Vasc Nurs; 2014 Sep; 32(3):99-104. PubMed ID: 25131756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease associated with androgen-deprivation therapy: time to give it due respect.
    Basaria S
    J Clin Oncol; 2015 Apr; 33(11):1232-4. PubMed ID: 25753444
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL; O'Malley A; Freedland SJ; Smith MR
    J Natl Cancer Inst; 2012 Oct; 104(19):1518-23. PubMed ID: 23210129
    [No Abstract]   [Full Text] [Related]  

  • 12. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them.
    Bolla M
    Eur Urol; 2015 Nov; 68(5):909-10. PubMed ID: 26460877
    [No Abstract]   [Full Text] [Related]  

  • 14. Does the benefit justify the risk?
    Albertsen PC
    J Natl Cancer Inst; 2010 Jan; 102(1):4-5. PubMed ID: 19996059
    [No Abstract]   [Full Text] [Related]  

  • 15. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
    Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Mitsuzuka K; Arai Y
    Int J Urol; 2018 Jan; 25(1):45-53. PubMed ID: 29052905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy in prostate cancer: looking beyond prostate-specific antigen and testosterone levels.
    Saad F
    Eur Urol; 2015 May; 67(5):837-8. PubMed ID: 25168615
    [No Abstract]   [Full Text] [Related]  

  • 18. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
    Griebling TL
    J Urol; 2014 Jun; 191(6):1784-5. PubMed ID: 25280283
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer: cardiovascular mortality and androgen deprivation.
    Basaria S
    Nat Rev Urol; 2009 May; 6(5):252-3. PubMed ID: 19424172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.